Abstract

In 2013, the term FT was introduced into the health sciences literature to describe the patient-level impacts of the cost of cancer care.2  Although the phenomenon had been studied prior, inconsistent terms and definitions hindered research. New nomenclature and conceptualization spurred the research community to investigate this important aspect of patient experience in a more harmonized approach. As we enter the second decade of FT research, a look back on what we have learned so far is warranted.